Clinical question
Can medications reduce the incidence of terminal respiratory secretions (death rattle) at the end of life?
Bottom line
Best evidence supports prophylactic administration of scopolamine butylbromide (Buscopan, hyoscine butylbromide) in patients close to death but without death rattle, which reduces the number who develop death rattle (13% vs 27% with placebo). Evidence supporting treatment of death rattle once it has begun is less clear, with no evidence that one anti-muscarinic is clearly superior to another. There is no evidence that treatment of death rattle improves patient comfort. It may, however, reduce the distress of people at bedside. Treatment decisions should be guided by conversations with family or caregivers.
Evidence
Prophylaxis
-
In 1 double-blind RCT,1 162 hospice patients in the dying phase (according to a multidisciplinary team) without death rattle were given scopolamine butylbromide, 20 mg subcutaneously 4 times daily, or placebo.
-
-
Development of death rattle (score of 2 or 3 on a 3-point scale, higher scores indicating worse condition) at any point prior to death: 13% versus 27% (placebo); number needed to treat of 8.
-
-
Adverse events (including restlessness, dry mouth, or urinary retention): no difference.
-
-
-
One non-blinded RCT2 with 132 adults close to death but without death rattle examined prophylaxis versus treatment at onset of death rattle with scopolamine butylbromide, 20 mg subcutaneously then 60 mg every 24 hours:
-
-
48% of patients suffered death rattle if treatment was initiated after symptoms were present, versus 6% of patients for whom treatment was initiated prior to symptom onset.
-
-
Treatment once death rattle presents
-
Four systematic reviews3-6 of 5 RCTs (10 to 333 participants) found the following.
-
-
Three RCTs found no difference between scopolamine hydrobromide and either atropine (1 RCT, 333 patients) or octreotide (1 RCT, 10 patients). Whether outcomes differed between scopolamine hydrobromide and glycopyrronium (1 RCT, 13 patients) was unclear.
-
-
Two RCTs found no difference between placebo and either atropine (1 RCT, 160 patients) or scopolamine hydrobromide (1 RCT, 31 patients).
-
-
Context
-
Death rattle is defined as noisy breathing caused by mucus in the upper respiratory tract.
Nonpharmacologic measures include physical repositioning, although evidence to support this is lacking.5
-
Scopolamine butylbromide (Buscopan) is available subcutaneously or orally in Canada.
-
-
Scopolamine hydrobromide is different and can cause central nervous system effects.8
-
-
Implementation
While glycopyrronium is commonly used for death rattle, there is little evidence of efficacy or tolerability. Prophylaxis with scopolamine butylbromide appears more effective than treatment once death rattle is established, so it is reasonable to consider in a patient’s dying phase. It is important to examine the reasons treatment is being explored, including patient and caregiver distress. Consideration of alternative supportive measures including reassurance and management of other symptoms (eg, pain or dyspnea) may provide greater comfort.
Tools for Practice articles in CFP are adapted from peer-reviewed articles at http://www.toolsforpractice.ca and summarize practice-changing medical evidence for primary care. Coordinated by Dr G. Michael Allan and Dr Adrienne J. Lindblad, articles are developed by the Patients, Experience, Evidence, Research (PEER) team and supported by the College of Family Physicians of Canada and its Alberta, Ontario, and Saskatchewan Chapters. Feedback is welcome at toolsforpractice@cfpc.ca.
Footnotes
Competing interests
None declared
References
- 1.Van Esch HJ, van Zuylan L, Geijteman ECT, Oomen-de Hoop E, Huisman BAA, Noordzij-Nooteboom HS, et al. Effect of prophylactic subcutaneous scopolamine butylbromide on death rattle in patients at the end of life: the SILENCE randomized clinical trial. JAMA 2021;326(13):1268-76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Mercadante S, Marinangeli F, Masedu F, Valenti M, Russo D, Ursini L, et al. Hyoscine butylbromide for the management of death rattle: sooner rather than later. J Pain Symptom Manage 2018;56(6):902-7. Epub 2018 Aug 31. [DOI] [PubMed] [Google Scholar]
- 3.Jansen K, Haugen DF, Pont L, Ruths S. Safety and effectiveness of palliative drug treatment in the last days of life—a systematic literature review. J Pain Symptom Manage 2018;55(2):508-21.e3. Epub 2017 Aug 10. [DOI] [PubMed] [Google Scholar]
- 4.Kolb H, Snowden A, Stevens E. Systematic review and narrative summary: treatments for and risk factors associated with respiratory tract secretions (death rattle) in the dying adult. J Adv Nurs 2018;74(7):1446-62. Epub 2018 Apr 6. [DOI] [PubMed] [Google Scholar]
- 5.Lokker ME, van Zuylen L, van der Rijt CCD, van der Heide A. Prevalence, impact, and treatment of death rattle: a systematic review. J Pain Symptom Manage 2014;47(1):105-22. Epub 2013 Jun 18. [DOI] [PubMed] [Google Scholar]
- 6.Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Sys Rev 2017;(1):CD005177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Crawford GB, Dzierżanowski T, Hauser K, Larkin P, Luque-Blanco AI, Murphy I, et al. Care of the adult cancer patient at the end of life: ESMO clinical practice guidelines. ESMO Open 2021;6(4):100225. Epub 2021 Aug 17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bennett M, Lucas V, Brennan M, Hughes A, O’Donnell V, Wee B. Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care. Palliat Med 2002;16(5):369-74. [DOI] [PubMed] [Google Scholar]